Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men

被引:211
作者
Djavan, B [1 ]
Zlotta, A
Remzi, M
Ghawidel, K
Basharkhah, A
Schulman, CC
Marberger, M
机构
[1] Univ Vienna, Dept Urol, Vienna, Austria
[2] Free Univ Brussels, Erasme Hosp, Dept Urol, B-1050 Brussels, Belgium
关键词
prostatic neoplasms; prostate-specific antigen; prostate; biopsy; prostatic hyperplasia;
D O I
10.1016/S0022-5347(05)67711-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose:We compare the ability of total prostate specific antigen (PSA), percent free PSA, PSA density and transition zone PSA density to predict the outcome of repeat prostatic biopsy in men with serum total PSA 4 to 10 ng./ml. who were diagnosed with benign prostatic hyperplasia after initial biopsy. Materials and Methods: In this prospective study 1,051 men with total PSA 4 to 10 ng./ml. underwent transrectal ultrasound guided sextant biopsy with 2 additional transition zone biopsies. In 254 subjects biopsy specimens were also obtained from suspicious areas identified during transrectal ultrasound and digital rectal examination. All subjects with biopsy specimens negative for prostate cancer underwent repeat biopsy 6 weeks after initial biopsy. The ability of total PSA, percent free PSA, PSA density and transition zone PSA density to improve the diagnostic power of PSA testing was assessed with univariate and multivariate analyses as well as receiver operating characteristics (ROC) curves. Results: Initial biopsy was positive (prostate cancer) in 231 and negative (benign prostatic hyperplasia) in 820 of the 1,051 subjects. Prostate cancer was detected on repeat biopsy in 10% of subjects (83 of 820) with negative initial biopsy. Percent free PSA and transition zone PSA density were the most accurate predictors of prostate cancer in these subjects. At a cutoff of 30% percent free PSA would have detected 90% of cancers (sensitivity) and eliminated 50% of unnecessary repeat biopsies (specificity). Sensitivity and specificity of transition zone PSA density at a cutoff of 0.26 ng./ml./cc was 78% and 52%, respectively. ROC curve analysis also showed that percent free PSA was a significantly better predictor of repeat biopsy results than total PSA, PSA density and transition zone PSA density. The area under the ROC curve was 74.5% for percent free PSA, 69.1% for transition zone PSA density, 61.8% for PSA density and 60.3% for total PSA. Conclusions: At least 10% of patients with negative initial prostatic biopsy results will be diagnosed with prostate cancer on repeat biopsy. Percent free PSA and transition zone PSA density enhance the specificity of PSA testing compared to total PSA or PSA density when determining which patients should undergo repeat biopsy. Repeat biopsy should be performed in patients with percent free PSA less than 30% or transition zone PSA density 0.26 ng./ml./cc or greater. In our study percent free PSA was the most accurate predictor of prostate cancer in repeat biopsy specimens.
引用
收藏
页码:1144 / 1148
页数:5
相关论文
共 33 条
[1]  
*AM CANC SOC, 1998, CANC FACTS FIG
[2]   The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population [J].
Bangma, CH ;
Rietbergen, JBW ;
Kranse, R ;
Blijenberg, BG ;
Petterson, K ;
Schroder, FH .
JOURNAL OF UROLOGY, 1997, 157 (06) :2191-2196
[3]   PROSPECTIVE EVALUATION OF PROSTATE-SPECIFIC ANTIGEN DENSITY AND SYSTEMATIC BIOPSIES FOR EARLY DETECTION OF PROSTATIC-CARCINOMA [J].
BAZINET, M ;
MESHREF, AW ;
TRUDEL, C ;
ARONSON, S ;
PELOQUIN, F ;
NACHABE, M ;
BEGIN, LR ;
ELHILALI, MM .
UROLOGY, 1994, 43 (01) :44-51
[4]   Percent free prostate-specific antigen: The next frontier in prostate-specific antigen testing [J].
Beduschi, M ;
Oesterling, JE .
UROLOGY, 1998, 51 (5A) :98-109
[5]   Prostate-specific antigen density [J].
Beduschi, MC ;
Oesterling, JE .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :323-&
[6]   PROSTATE-SPECIFIC ANTIGEN - CRITICAL ISSUES [J].
BRAWER, MK .
UROLOGY, 1994, 44 (6A) :9-17
[7]   Prostate-specific antigen velocity and repeated measures of prostate-specific antigen [J].
Carter, HB ;
Pearson, JD .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :333-&
[8]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[9]  
CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
[10]   Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies [J].
Catalona, WJ ;
Beiser, JA ;
Smith, DS .
JOURNAL OF UROLOGY, 1997, 158 (06) :2162-2167